Correlation Between 4D Molecular and Madrigal Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both 4D Molecular and Madrigal Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining 4D Molecular and Madrigal Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between 4D Molecular Therapeutics and Madrigal Pharmaceuticals, you can compare the effects of market volatilities on 4D Molecular and Madrigal Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in 4D Molecular with a short position of Madrigal Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of 4D Molecular and Madrigal Pharmaceuticals.

Diversification Opportunities for 4D Molecular and Madrigal Pharmaceuticals

-0.33
  Correlation Coefficient

Very good diversification

The 3 months correlation between FDMT and Madrigal is -0.33. Overlapping area represents the amount of risk that can be diversified away by holding 4D Molecular Therapeutics and Madrigal Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Madrigal Pharmaceuticals and 4D Molecular is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on 4D Molecular Therapeutics are associated (or correlated) with Madrigal Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Madrigal Pharmaceuticals has no effect on the direction of 4D Molecular i.e., 4D Molecular and Madrigal Pharmaceuticals go up and down completely randomly.

Pair Corralation between 4D Molecular and Madrigal Pharmaceuticals

Given the investment horizon of 90 days 4D Molecular Therapeutics is expected to under-perform the Madrigal Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, 4D Molecular Therapeutics is 1.98 times less risky than Madrigal Pharmaceuticals. The stock trades about -0.03 of its potential returns per unit of risk. The Madrigal Pharmaceuticals is currently generating about 0.29 of returns per unit of risk over similar time horizon. If you would invest  21,779  in Madrigal Pharmaceuticals on August 30, 2024 and sell it today you would earn a total of  11,366  from holding Madrigal Pharmaceuticals or generate 52.19% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

4D Molecular Therapeutics  vs.  Madrigal Pharmaceuticals

 Performance 
       Timeline  
4D Molecular Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days 4D Molecular Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's primary indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
Madrigal Pharmaceuticals 

Risk-Adjusted Performance

9 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Madrigal Pharmaceuticals are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite quite uncertain technical and fundamental indicators, Madrigal Pharmaceuticals disclosed solid returns over the last few months and may actually be approaching a breakup point.

4D Molecular and Madrigal Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with 4D Molecular and Madrigal Pharmaceuticals

The main advantage of trading using opposite 4D Molecular and Madrigal Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if 4D Molecular position performs unexpectedly, Madrigal Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Madrigal Pharmaceuticals will offset losses from the drop in Madrigal Pharmaceuticals' long position.
The idea behind 4D Molecular Therapeutics and Madrigal Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Other Complementary Tools

Share Portfolio
Track or share privately all of your investments from the convenience of any device
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Fundamental Analysis
View fundamental data based on most recent published financial statements
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.